Feb 19, 2020   SOURCE: PR NewsWire

2020 Geographic Atrophy (GA) Pipeline Insights Report

DUBLIN, Feb. 19, 2020 /PRNewswire/ -- The "Geographic Atrophy (GA) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Geographic Atrophy (GA) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Geographic Atrophy (GA) market.

A detailed picture of the Geographic Atrophy (GA) pipeline landscape is provided, which includes the disease overview and Geographic Atrophy (GA) treatment guidelines. The assessment part of the report embraces in-depth Geographic Atrophy (GA) commercial assessment and clinical assessment of the Geographic Atrophy (GA) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Geographic Atrophy (GA) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

    --  All of the companies that are developing therapies for the treatment of
        Geographic Atrophy (GA) with aggregate therapies developed by each
        company for the same.
    --  Different therapeutic candidates segmented into early-stage, mid-stage
        and late stage of development for the Geographic Atrophy (GA) treatment.
    --  Geographic Atrophy (GA) key players involved in targeted therapeutics
        development with respective active and inactive (dormant or
        discontinued) projects.
    --  Drugs under development based on the stage of development, route of
        administration, target receptor, monotherapy or combination therapy, a
        different mechanism of action, and molecular type.
    --  Detailed analysis of collaborations (company-company collaborations and
        company-academia collaborations), licensing agreement and financing
        details for future advancement of Geographic Atrophy (GA) market.

Scope of the Report

    --  The Geographic Atrophy (GA) report provides an overview of therapeutic
        pipeline activity and therapeutic assessment of the products by
        development stage, product type, route of administration, molecule type,
        and MOA type for Geographic Atrophy (GA) across the complete product
        development cycle, including all clinical and nonclinical stages.
    --  It comprises of detailed profiles of Geographic Atrophy (GA) therapeutic
        products with key coverage of developmental activities, including
        technology, collaborations, licensing, mergers and acquisition, funding,
        designations and other product-related details
    --  Detailed Geographic Atrophy (GA) research and development progress and
        trial details, results wherever available, are also included in the
        pipeline study.
    --  Coverage of dormant and discontinued pipeline projects along with the
        reasons if available across Geographic Atrophy (GA).

Key Questions Answered

    --  What are the current options for Geographic Atrophy (GA) treatment?
    --  How many companies are developing therapies for the treatment of
        Geographic Atrophy (GA)?
    --  What are the principal therapies developed by these companies in the
        industry?
    --  How many therapies are developed by each company for the treatment of
        Geographic Atrophy (GA)?
    --  How many Geographic Atrophy (GA) emerging therapies are in early-stage,
        mid-stage, and late stage of development for the treatment of Geographic
        Atrophy (GA)?
    --  Out of total pipeline products, how many therapies are given as a
        monotherapy and in combination with other therapies?
    --  What are the key collaborations (Industry-Industry, Industry-Academia),
        Mergers and acquisitions, and major licensing activities that will
        impact Geographic Atrophy (GA) market?
    --  Which are the dormant and discontinued products and the reasons for the
        same?
    --  What is the unmet need for current therapies for the treatment of
        Geographic Atrophy (GA)?
    --  What are the recent novel therapies, targets, mechanisms of action and
        technologies developed to overcome the limitation of existing Geographic
        Atrophy (GA) therapies?
    --  What are the clinical studies going on for Geographic Atrophy (GA) and
        their status?
    --  What are the results of the clinical studies and their safety and
        efficacy?
    --  What are the key designations that have been granted for the emerging
        therapies for Geographic Atrophy (GA)?
    --  How many patents are granted and pending for the emerging therapies for
        the treatment of Geographic Atrophy (GA)?

Companies Mentioned 

    --  NGM Biopharmaceuticals Inc
    --  Apellis Pharmaceuticals Inc.
    --  Ophthotech Corporation
    --  Genentech Inc.
    --  Ionis Pharmaceuticals Inc.
    --  Alkeus Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sjxdzt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/2020-geographic-atrophy-ga-pipeline-insights-report-301007448.html

SOURCE Research and Markets